Jose M. Sanchez - Publications

Molecular Divergence upon EGFR-TKI Resistance Could Be Dependent on the Exon Location of the Original EGFR-Sensitizing Mutation.

Journal: Cancers

Published: August 19, 2022

First-line osimertinib in patients with epidermal growth factor receptor-mutant non-small-cell lung cancer and with a coexisting low allelic fraction of Thr790Met.

Journal: European journal of cancer (Oxford, England : 1990)

Published: June 18, 2021

Efficacy of nintedanib plus docetaxel in patients with refractory advanced epidermal growth factor receptor mutant lung adenocarcinoma.

Journal: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico

Published: April 02, 2021

NGS-based liquid biopsy profiling identifies mechanisms of resistance to ALK inhibitors: a step toward personalized NSCLC treatment.

Journal: Molecular oncology

Published: January 13, 2021

Phase II clinical trial with metronomic oral vinorelbine and tri-weekly cisplatin as induction therapy, subsequently concomitant with radiotherapy (RT) in patients with locally advanced, unresectable, non-small cell lung cancer (NSCLC). Analysis of survival and value of ctDNA for patient selection.

Journal: Lung cancer (Amsterdam, Netherlands)

Published: October 16, 2020

Analysis of circulating tumour DNA to identify patients with epidermal growth factor receptor-positive non-small cell lung cancer who might benefit from sequential tyrosine kinase inhibitor treatment.

Journal: European journal of cancer (Oxford, England : 1990)

Published: September 07, 2020

Co-activation of STAT3 and YES-Associated Protein 1 (YAP1) Pathway in EGFR-Mutant NSCLC.

Journal: Journal of the National Cancer Institute

Published: August 02, 2016

Economic Analysis of First-Line Treatment with Erlotinib in an EGFR-Mutated Population with Advanced NSCLC.

Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer

Published: December 01, 2015

Association of EGFR L858R Mutation in Circulating Free DNA With Survival in the EURTAC Trial.

Journal: JAMA oncology

Published: July 17, 2015

Two biomarker-directed randomized trials in European and Chinese patients with nonsmall-cell lung cancer: the BRCA1-RAP80 Expression Customization (BREC) studies.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: August 29, 2014

Differential effect of MMSET mRNA levels on survival to first-line FOLFOX and second-line docetaxel in gastric cancer.

Journal: British journal of cancer

Published: January 24, 2014

Are we ready to use biomarkers for staging, prognosis and treatment selection in early-stage non-small-cell lung cancer?

Journal: Translational lung cancer research

Published: February 10, 2013